Skip to main content
TipRanks
Go Ultimate75% OFF

Celon Pharma SA (8RP) AI Stock Analysis

2 Followers
DE:8RP

Celon Pharma SA

(Frankfurt:8RP)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Gross Profit MarginA strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability as the company scales.
Negative Factors
Negative Revenue GrowthNegative revenue growth suggests challenges in maintaining sales momentum, which can hinder long-term business sustainability and market competitiveness.

Celon Pharma SA (8RP) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%30%DE:8RP-27.42%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 189.32M
Dividend Yield
―
Average Volume (3M)
57
Price to Earnings (P/E)
7.4
Beta (1Y)
0.30
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
560
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Celon Pharma SA Business Overview & Revenue Model

Company Description

Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic dru...

Celon Pharma SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:8RP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PL:BIOPL:BIO45NeutralPLN 297.09M-25.18-1.97%―-15.67%-307.60%
PL:MABPL:MAB41NeutralPLN 152.57M-2.70-159.09%―11.57%4.35%
PL:RVUPL:RVU37UnderperformPLN 390.73M-5.61-139.66%―-11.57%43.60%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%DE:8RPPL:RVUPL:SVEPL:BIOPL:MOCPL:MABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:8RP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:8RPCelon Pharma SA3.42-1.45-29.73%
PL:RVURyvu Therapeutics SA16.90-7.20-29.88%
PL:SVEBiomed-Lublin Wytwornia Surowic i Szczepionek S.A.2.67-1.35-33.58%
PL:BIOBIOTON S.A.3.46-0.46-11.73%
PL:MOCOncoArendi Therapeutics SA5.38-0.67-11.07%
PL:MABMabion SA9.441.9125.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.